2. Academic Validation
  3. Turning a Substrate Peptide into a Potent Inhibitor for the Histone Methyltransferase SETD8

Turning a Substrate Peptide into a Potent Inhibitor for the Histone Methyltransferase SETD8

  • ACS Med Chem Lett. 2016 Oct 11;7(12):1102-1106. doi: 10.1021/acsmedchemlett.6b00303.
Russell A Judge 1,  Haizhong Zhu 1,  Anup K Upadhyay 1,  Pierre M Bodelle 1,  Charles W Hutchins 1,  Maricel Torrent 1,  Violeta L Marin 1,  Wenyu Yu 2,  Masoud Vedadi 2,  Fengling Li 2,  Peter J Brown 2,  William N Pappano 1,  Chaohong Sun 1,  Andrew M Petros 1
Affiliations

Affiliations

  • 1 AbbVie Inc. , 1 North Waukegan Road, North Chicago, Illinois 60064, United States.
  • 2 Structural Genomics Consortium, University of Toronto , 101 College Street, Toronto, ON M5G 1L7, Canada.
PMID: 27994746 DOI: 10.1021/acsmedchemlett.6b00303
Abstract

SETD8 is a histone H4-K20 methyltransferase that plays an essential role in the maintenance of genomic integrity during mitosis and in DNA damage repair, making it an intriguing target for Cancer research. While some small molecule inhibitors for SETD8 have been reported, the structural binding modes for these inhibitors have not been revealed. Using the complex structure of the substrate peptide bound to SETD8 as a starting point, different natural and unnatural amino acid substitutions were tested, and a potent (Ki 50 nM, IC50 0.33 μM) and selective norleucine containing peptide inhibitor has been obtained.

Keywords

HMT; SETD8; cancer; drug design; structure-based drug design.

Figures
Products
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z